Svoboda | Graniru | BBC Russia | Golosameriki | Facebook

Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022

MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):264-270. doi: 10.15585/mmwr.mm7107e3.

Abstract

COVID-19 vaccination is recommended for persons who are pregnant, breastfeeding, trying to get pregnant now, or who might become pregnant in the future, to protect them from COVID-19.§ Infants are at risk for life-threatening complications from COVID-19, including acute respiratory failure (1). Evidence from other vaccine-preventable diseases suggests that maternal immunization can provide protection to infants, especially during the high-risk first 6 months of life, through passive transplacental antibody transfer (2). Recent studies of COVID-19 vaccination during pregnancy suggest the possibility of transplacental transfer of SARS-CoV-2-specific antibodies that might provide protection to infants (3-5); however, no epidemiologic evidence currently exists for the protective benefits of maternal immunization during pregnancy against COVID-19 in infants. The Overcoming COVID-19 network conducted a test-negative, case-control study at 20 pediatric hospitals in 17 states during July 1, 2021-January 17, 2022, to assess effectiveness of maternal completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization in infants. Among 379 hospitalized infants aged <6 months (176 with COVID-19 [case-infants] and 203 without COVID-19 [control-infants]), the median age was 2 months, 21% had at least one underlying medical condition, and 22% of case- and control-infants were born premature (<37 weeks gestation). Effectiveness of maternal vaccination during pregnancy against COVID-19 hospitalization in infants aged <6 months was 61% (95% CI = 31%-78%). Completion of a 2-dose mRNA COVID-19 vaccination series during pregnancy might help prevent COVID-19 hospitalization among infants aged <6 months.

MeSH terms

  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / immunology*
  • Case-Control Studies
  • Female
  • Hospitalization / statistics & numerical data*
  • Hospitals, Pediatric
  • Humans
  • Immunity, Maternally-Acquired*
  • Immunization, Passive
  • Infant
  • Infant, Newborn
  • Pregnancy
  • SARS-CoV-2 / immunology*
  • United States / epidemiology
  • Vaccines, Synthetic / immunology*
  • mRNA Vaccines / immunology*

Substances

  • COVID-19 Vaccines
  • Vaccines, Synthetic
  • mRNA Vaccines